NEW

Study Confirms Surfacide UV-C Kills SARS-CoV-2

A recent peer-reviewed study in the Journal of Clinical Anesthesia* found the Surfacide Helios® System UV-C technology is nearly 95% effective in preventing SARS CoV-2 in patient environments. This is the first clinical study that evaluates the use of UV-C in...

AORN Recommends Nasal Decolonization with PVP-I

The Association of periOperative Registered Nurses (AORN) has announced its annual updated recommendations on the "Guideline for Preoperative Skin Antisepsis," to assist health care professionals in navigating risk-based decisions for developing preoperative...

New AAAHC Quality Roadmap Probes Data, Highlights Surveyor Insights

On June 16, AAAHC released its 2021 Quality Roadmap, a comprehensive analysis of data from more than 1,120 accreditation surveys conducted in 2020.

RSIP Vision Reveals New Module

RSIP Vision has announced its new surgical workflow analysis technology, which can intelligently identify each separate stage of a surgical procedure and label them accordingly throughout the duration of the procedure.

First-in-Human Clinical Feasibility Trial of NaviSci System Announced

Navigation SciencesNavigation Sciences has announced that the initial patient has participated in the first-in-human clinical feasibility trial of its NaviSci System for use in minimally invasive surgery to remove probable early-stage lung tumors. The Intelligent Surgery System, which integrates Augmented Reality and advanced software with surgical instruments, is the first designed to provide real-time measurement of surgical margins that are critical to reducing the risk of cancer recurrence and conserving lung function.

“The growing number of lung cancer patients diagnosed at an early stage, when resection is potentially curative, along with increasing use of tissue-sparing surgical approaches such as wedge resection and segmentectomy, have potential to significantly improve patient outcomes,” said the trial’s principal investigator Scott Swanson, MD, director of minimally invasive thoracic surgery at Brigham and Women’s Hospital and associate chief of surgery at the Dana-Farber/Brigham and Women’s Cancer Center. “In this setting, resection with the appropriate margin is both essential and challenging. This trial will provide the first opportunity to evaluate in patients during surgery the potential of a system that provides real-time ‘GPS’ guidance to the surgeon to determine the margin distance.”

The clinical feasibility trial, “Navigated Resection of Lung Nodules,” will evaluate NaviSci’s safety and ability to measure surgical margins in real time in 25 patients undergoing lung surgery, as well as evaluate the system’s potential to integrate and improve the surgical workflow. The study is being conducted at Brigham and Women’s Hospital in Boston.

“The clinical trial marks an important milestone for the NaviSci System’s development and the company,” said Alan D. Lucas, co-founder, and CEO of Navigation Sciences. “The NaviSci System and Intelligent Surgical approaches have great potential to dramatically increase the precision of lung and other complex cancer surgeries, improving patient outcomes and providing benefits to clinicians and providers. Successful completion of the trial will support an application to the FDA for U.S. marketing clearance.”

The NaviSci System enables the physician in real-time to know precisely where the target potential tumor nodule and surrounding tissue are in relationship to the surgical instrumentation and guide the surgeon on margin distance for excising the nodule. The system consists of several key components, including:

  • active, fiducial marker with an electromagnetic sensor (called a J-Bar) that is placed next to the tumor to localize and track its position.
  • a surgical cutting instrument with a second electromagnetic position sensor and, proprietary software that links the sensors on the tumor with the cutting instruments and provides visual as well as quantitative information to measure tumor margins in real-time.

There are more than 225,000 new cases of lung cancer diagnosed in the U.S. annually, of which more than 76,000 are early-stage tumors. The number of early-stage diagnoses is expected to grow significantly with increased adoption of CT X-ray screening and favorable reimbursement coverage. The growth is likely to be driven in part by a recent recommendation by the U.S. Preventative Services Task Force that the annual screening population be more than doubled, from 6.4 million to 14.5 million people.

Learn more here.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X